PT - JOURNAL ARTICLE AU - Huffman, Jennifer AU - Butler-Laporte, Guillaume AU - Khan, Atlas AU - Drivas, Theodore G. AU - Peloso, Gina M. AU - Nakanishi, Tomoko AU - Verma, Anurag AU - Kiryluk, Krzysztof AU - Richards, J. Brent AU - Zeberg, Hugo TI - Alternative splicing of <em>OAS1</em> alters the risk for severe COVID-19 AID - 10.1101/2021.03.20.21254005 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.20.21254005 4099 - http://medrxiv.org/content/early/2021/03/25/2021.03.20.21254005.short 4100 - http://medrxiv.org/content/early/2021/03/25/2021.03.20.21254005.full AB - A locus containing OAS1/2/3 has been identified as a risk locus for severe COVID-19 among Europeans ancestry individuals, with a protective haplotype of ∼75 kilobases derived from Neanderthals. Here, we show that among several potentially causal variants at this locus, a splice variant of OAS1 occurs in people of African ancestry independently of the Neanderthal haplotype and confers protection against COVID-19 of a magnitude similar to that seen in individuals without African ancestry.Competing Interest StatementThe authors have declared no competing interest.Funding StatementGenotyping and phenotyping of the Columbia University cohort was made possible by the Columbia University COVID-19 Biobank Genomics Workgroup members, including Richard Mayeux, Muredach P. Reilly, Wendy Chung, David B. Goldstein, Christine K. Garcia, Iuliana Ionita-Laza, Andrea Califano, Sheila M. O'Byrne, Danielle Pendrick, Soumitra Sengupta, Peter Sims, and Anne-Catrin Uhlemann. The Columbia University COVID-19 Biobank was supported by Columbia University and the National Center for Advancing Translational Sciences, NIH, through Grant Number UL1TR001873. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The Richards research group is supported by the Canadian Institutes of Health Research (CIHR) (365825 and 409511), the Lady Davis Institute of the Jewish General Hospital, the Canadian Foundation for Innovation (CFI), the NIH Foundation, Cancer Research UK, Genome Quebec, the Public Health Agency of Canada, the McGill Interdisciplinary Initiative in Infection and Immunity and the Fonds de Recherche Quebec Sante (FRQS). GBL is supported by a CIHR scholarship and a joint FRQS and Quebec Ministry of Health and Social Services scholarship. TN is supported by a research fellowship of the Japan Society for the Promotion of Science for Young Scientists. JBR is supported by an FRQS Clinical Research Scholarship. Support from Calcul Quebec and Compute Canada is acknowledged. TwinsUK is funded by the Welcome Trust, the Medical Research Council, the European Union, the National Institute for Health Research-funded BioResource and the Clinical Research Facility and Biomedical Research Centre based at Guy's and St. Thomas' NHS Foundation Trust in partnership with King's College London. The Biobanque Quebec COVID19 is funded by FRQS, Genome Quebec and the Public Health Agency of Canada, the McGill Interdisciplinary Initiative in Infection and Immunity and the Fonds de Recherche Quebec Sante. HZ is supported by Jeanssons Stiftelser and Magnus Bergsvalls Stiftelse. These funding agencies had no role in the design, implementation or interpretation of this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The collection of samples to the Penn Medicine Biobank was approved by the Institutional Review Board of Perelman School of Medicine at University of Pennsylvania. The collection of samples to the Columbia University COVID-19 Biobank was approved by the Institutional Review Board (IRB) of Columbia University (IRB protocol number AAAS7370), while the genetic analyses were approved under Columbia University IRB protocol number AAAS7948. All participants gave appropriate consent and ethical approvals were obtained from the relevant research ethics boards.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data necessary to reproduce the findings can be found within the manuscript. https://www.covid19hg.org/ https://www.internationalgenome.org/